Thomas Nee, Principal at Larchmont Ventures, is a commercial valuation and strategic marketing executive with extensive experience evaluating deals and driving acquisition strategy in fast-moving, high-growth businesses. He has broad and deep financial expertise, gained through lengthy periods of product and business assessment at global pharmaceutical companies seeking rapid growth in revenue and market share. He is analytics-focused, adept at developing best-case and alternate-case scenarios for strategic planning, and skilled at driving organizational change across borders and cultures.
Currently, he is an Operating Partner at a lower-middle market healthcare private equity firm where he advises on commercial strategy and research across portfolio companies and investment opportunities. He also serves on the Mid-Atlantic Bio Angels Steering Committee and Screening Committee.
His commercial experience comes from multiple positions at Allergan, Forest Laboratories, and Procter & Gamble, where Thomas had grown products and made the business case for products that have generated billions of dollars in annual revenue. He has assessed the commercial viability of hundreds of internal and external assets, and built the infrastructure and measurement systems to gauge opportunities and evaluate successes.
In his most recent position as Senior Vice President, Business Analytics & Operations at Allergan, Thomas led a diverse team of financial and creative experts that evaluated 150 to 170 external assets a year for a US pharmaceutical division in high-energy acquisition mode. That work resulted in 17 acquisitions, franchise deals or other partnerships over two years. Thomas was also responsible for market research and analytics, digital and consumer marketing, and marketing operations.
Previously, Thomas was Senior Vice President, Global Commercial Assessments and Market Research for Forest Laboratories, where he led the commercial evaluation of potential acquisitions and licensing deals as the company repopulated its pipeline because of upcoming product expirations. He led the commercial evaluation and created the framework for four major deals that contributed $3 billion in revenue in 2016.
Thomas also served as Vice President, Commercial Assessments, New Products, where he led the commercial advocacy for a dozen acquisitions that generated $1.3 billion in annual revenue. Those assets became the core of Forest’s ultimate take-out value, when it was acquired by Actavis in 2014. (Actavis acquired Allergan, and took its name, in 2015.)
Earlier, Thomas served various product management roles at Forest and at Procter & Gamble.
Thomas has an MBA from the Stanford Graduate School of Business. He has a BS in Biology, with specializations in Chemistry and Psychology from Santa Clara University.